243 related articles for article (PubMed ID: 8662094)
1. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
4. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
Bassa P; Kim EE; Inoue T; Wong FC; Korkmaz M; Yang DJ; Wong WH; Hicks KW; Buzdar AU; Podoloff DA
J Nucl Med; 1996 Jun; 37(6):931-8. PubMed ID: 8683314
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
Crowe JP; Adler LP; Shenk RR; Sunshine J
Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
12. [Detection of multi-focal breast carcinoma using 2[18F] fluoro-deoxy-D-glucose positron emission tomography (FDG-PET)].
Scharl A; Scheidhauer K; Pietrzyk U; Göhring UJ; Schomäcker K
Geburtshilfe Frauenheilkd; 1996 Aug; 56(8):434-7. PubMed ID: 8974899
[TBL] [Abstract][Full Text] [Related]
13. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
[TBL] [Abstract][Full Text] [Related]
14. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
15. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
Zhao TT; Li JG; Li YM
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638
[TBL] [Abstract][Full Text] [Related]
16. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
Nieweg OE; Kim EE; Wong WH; Broussard WF; Singletary SE; Hortobagyi GN; Tilbury RS
Cancer; 1993 Jun; 71(12):3920-5. PubMed ID: 8389655
[TBL] [Abstract][Full Text] [Related]
18. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
19. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
